{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:39:05Z","timestamp":1790314745833,"version":"4.1.0"},"reference-count":7,"publisher":"S. Karger AG","issue":"12","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Introduction:<\/i><\/b> Lutetium-177 (<sup>177<\/sup>Lu)-DOTATATE received FDA approval in 2018 to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs). Little data are available on response and outcomes for well-differentiated (WD) high-grade (HG) NETs treated with <sup>177<\/sup>Lu-DOTATATE. <b><i>Materials and Methods:<\/i><\/b> Patients with WD HG NETs treated with <sup>177<\/sup>Lu-DOTATATE at MSK from 2018 to 2020 were identified. Demographics, response (RECIST 1.1), and progression-free survival (PFS) were determined. Next-generation sequencing (NGS) was performed in the archival tumor. <b><i>Results:<\/i><\/b> Nineteen patients, all with progressive, heavily treated disease, were identified. Sites of tumor origin were: pancreas (74%), small bowel (11%), rectum (11%), and lung (5%); median Ki-67 was 32% (range 22\u201356). Thirteen patients (68%) completed all four <sup>177<\/sup>Lu-DOTATATE cycles. Best response (<i>N<\/i> = 18 evaluable) was: 5\/18 (28%) partial response, 8\/18 (44%) stable disease, and 5\/18 (28%) disease progression. Median PFS was 13.1 months (95% CI: 8.7\u201320.9). Most common treatment-related toxicities were thrombocytopenia (9 patients, 47%; G3\/4, 1 patient, 5%), anemia (7 patients, 37%; G3\/4, 2 patients, 11%), leukopenia (6 patients, 32%; G3\/4, 0 patients), and liver function test elevation (4 patients, 21%; G3\/4, 0 patients). NGS results were available from 13\/19 tumors (68%). The most observed alterations were in MEN1 (6\/13, 46%) and DAXX (4\/13, 31%). No RB1 alterations identified. <b><i>Conclusion:<\/i><\/b> We observed a meaningful disease control rate of 72% during treatment of WD HG NETs with <sup>177<\/sup>Lu-DOTATATE. In this heavily pre-treated population, more than half of patients received all four treatment cycles with toxicities largely bone marrow-related. As would be expected in WD NETs, the vast majority had alterations in chromatin remodeling genes and no RB1 alterations. <\/jats:p>","DOI":"10.1159\/000525216","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T21:00:36Z","timestamp":1653426036000},"page":"1177-1186","source":"Crossref","is-referenced-by-count":15,"title":["Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE"],"prefix":"10.1159","volume":"112","author":[{"given":"Nitya","family":"Raj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Coffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-0310","authenticated-orcid":false,"given":"Richard Kinh Gian","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7854","authenticated-orcid":false,"given":"Johnathan","family":"Rafailov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne F.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-3193","authenticated-orcid":false,"given":"Marinela","family":"Capanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dunphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-3475","authenticated-orcid":false,"given":"Josef J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder K.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7501-8676","authenticated-orcid":false,"given":"Ryan P.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-4185","authenticated-orcid":false,"given":"Heiko","family":"Schoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-7383","authenticated-orcid":false,"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Reidy-Lagunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1184-3"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.002"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510015"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.066134"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1486-0"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.04.008"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.215848"}],"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/525216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/525216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:02:09Z","timestamp":1745420529000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000525216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":7,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,11,16]]},"published-print":{"date-parts":[[2022,11,29]]}},"URL":"https:\/\/doi.org\/10.1159\/000525216","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}